135 related articles for article (PubMed ID: 6391145)
1. MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas.
Sternberg CN; Magill GB; Sordillo PP; Cheng EW
Am J Clin Oncol; 1984 Oct; 7(5):529-33. PubMed ID: 6391145
[TBL] [Abstract][Full Text] [Related]
2. 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas.
Smith FP; Hoth DF; Levin B; Karlin DA; MacDonald JS; Woolley PV; Schein PS
Cancer; 1980 Nov; 46(9):2014-8. PubMed ID: 7427908
[TBL] [Abstract][Full Text] [Related]
3. Activity of 5-fluorouracil, mitomycin C, and methyl CCNU in inoperable adenocarcinoma of pancreas.
Vaughn C; Chapman J; Chinn B; Ward D; Groshko G; Maniscalco B; Reznik S; Piper D
Am J Clin Oncol; 1989 Feb; 12(1):49-52. PubMed ID: 2492142
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM).
Oster MW; Gray R; Panasci L; Perry MC
Cancer; 1986 Jan; 57(1):29-33. PubMed ID: 2934124
[TBL] [Abstract][Full Text] [Related]
5. 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary.
Goldberg RM; Smith FP; Ueno W; Ahlgren JD; Schein PS
J Clin Oncol; 1986 Mar; 4(3):395-9. PubMed ID: 3754004
[TBL] [Abstract][Full Text] [Related]
6. Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion.
Bruckner HW; Kalman J; Spigelman M; Gorbaty MI; Butwell N; Storch J; McKenna A
Oncology; 1989; 46(6):366-71. PubMed ID: 2511535
[TBL] [Abstract][Full Text] [Related]
7. Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas.
Karlin DA; Stroehlein JR; Bennetts RW; Jones RD; Heifetz LJ; Mahal PS
Cancer Treat Rep; 1982 Aug; 66(8):1613-7. PubMed ID: 7105051
[TBL] [Abstract][Full Text] [Related]
8. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.
Cullinan SA; Moertel CG; Fleming TR; Rubin JR; Krook JE; Everson LK; Windschitl HE; Twito DI; Marschke RF; Foley JF
JAMA; 1985 Apr; 253(14):2061-7. PubMed ID: 2579257
[TBL] [Abstract][Full Text] [Related]
9. 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) in the treatment of inoperable adenocarcinoma of the lung.
Shepherd FA; Evans WK; Burkes R; Paul K; DeBoer G
Am J Clin Oncol; 1986 Oct; 9(5):392-6. PubMed ID: 3776901
[TBL] [Abstract][Full Text] [Related]
10. Phase-III clinical trial of adjuvant FAM2 (5-FU, adriamycin and mitomycin C) vs control in resectable gastric cancer: a study of the EORTC Gastrointestinal Tract Cancer Cooperative Group.
Lise M; Nitti D; Buyse M; Cartei G; Fornasiero A; Guimaraes dos Santos J; Duez N
Recent Results Cancer Res; 1988; 110():36-43. PubMed ID: 3043595
[No Abstract] [Full Text] [Related]
11. Combination chemotherapy for locally advanced pancreatic cancer: equivalence to external beam irradiation and implication for future management.
Smith FP; Stablein D; Korsmeyer S; Neefe J; Chun BK; Woolley PV; Schein PS
J Clin Oncol; 1983 Jul; 1(7):413-5. PubMed ID: 6689426
[TBL] [Abstract][Full Text] [Related]
12. Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C.
Cunningham D; Soukop M; McArdle CS; Carter DC; Smyth JF; Allan SG; Kaye SB; Sangster G; Calman KC; Hutcheon AW
Br J Surg; 1984 Sep; 71(9):673-6. PubMed ID: 6548166
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of 5-fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinoma.
Bukowski RM; Schacter LP; Groppe CW; Hewlett JS; Weick JK; Livingston RB
Cancer; 1982 Jul; 50(2):197-200. PubMed ID: 6211223
[TBL] [Abstract][Full Text] [Related]
14. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin.
Cullinan S; Moertel CG; Wieand HS; Schutt AJ; Krook JE; Foley JF; Norris BD; Kardinal CG; Tschetter LK; Barlow JF
Cancer; 1990 May; 65(10):2207-12. PubMed ID: 2189551
[TBL] [Abstract][Full Text] [Related]
15. Further studies on the treatment of advanced gastric cancer by 5-fluorouracil, Adriamycin (doxorubicin), and mitomycin C (modified FAM).
Haim N; Epelbaum R; Cohen Y; Robinson E
Cancer; 1984 Nov; 54(9):1999-2002. PubMed ID: 6548173
[TBL] [Abstract][Full Text] [Related]
16. 5-fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer.
MacDonald JS; Woolley PV; Smythe T; Ueno W; Hoth D; Schein PS
Cancer; 1979 Jul; 44(1):42-7. PubMed ID: 455263
[TBL] [Abstract][Full Text] [Related]
17. Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group.
J Clin Oncol; 1986 Dec; 4(12):1794-8. PubMed ID: 2946815
[TBL] [Abstract][Full Text] [Related]
18. 5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary.
van der Gaast A; Verweij J; Planting AS; Stoter G
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):765-8. PubMed ID: 3383976
[TBL] [Abstract][Full Text] [Related]
19. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma.
Kelsen D; Hudis C; Niedzwiecki D; Dougherty J; Casper E; Botet J; Vinciguerra V; Rosenbluth R
Cancer; 1991 Sep; 68(5):965-9. PubMed ID: 1833042
[TBL] [Abstract][Full Text] [Related]
20. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Kim NK; Park YS; Heo DS; Suh C; Kim SY; Park KC; Kang YK; Shin DB; Kim HT; Kim HJ
Cancer; 1993 Jun; 71(12):3813-8. PubMed ID: 8508349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
